"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 8 | 1 | 9 |
| 2010 | 3 | 3 | 6 |
| 2011 | 9 | 6 | 15 |
| 2012 | 7 | 4 | 11 |
| 2013 | 6 | 3 | 9 |
| 2014 | 3 | 1 | 4 |
| 2015 | 3 | 2 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab. 2023 05; 25(5):1413-1418.
-
Digital imaging software versus the "eyeball" method in quantifying steatosis in a liver biopsy. Liver Transpl. 2023 03 01; 29(3):268-278.
-
Practice patterns of the medical evaluation of living liver donors in the United States. Liver Transpl. 2023 02 01; 29(2):164-171.
-
Optimal surgical workup to ensure safe recovery of the donor after living liver donation - A systematic review of the literature and expert panel recommendations. Clin Transplant. 2022 10; 36(10):e14641.
-
Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Aliment Pharmacol Ther. 2022 02; 55(4):479-480.
-
Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta. Thyroid. 2021 07; 31(7):1127-1134.
-
Neither amyloid depositions nor hepatic steatosis are associated with marginal islet mass early after autotransplantation. Am J Transplant. 2021 05; 21(5):1985-1987.
-
Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020 09 01; 319(3):G333-G344.
-
Broad-spectrum antibiotics alter the microbiome, increase intestinal fxr, and decrease hepatic steatosis in zebrafish short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2020 08 01; 319(2):G212-G226.
-
Bone morphogenetic protein 4 (BMP4) alleviates hepatic steatosis by increasing hepatic lipid turnover and inhibiting the mTORC1 signaling axis in hepatocytes. Aging (Albany NY). 2019 12 12; 11(23):11520-11540.